Handling of doripenem sterile API for dry-powder vial filling begins from the constraint that terminal steam sterilization is not viable for the β-lactam nucleus. The API is therefore filled as a pre-sterilized crystalline monohydrate with controlled residual water into depyrogenated Type I borosilicate glass vials under EU GMP Annex 1 Grade A conditions. Aseptic crystallization from an aqueous/organic solvent system is carried out with controlled nucleation, and the milled or sieved powder is vacuum-dried below the dehydration threshold of the monohydrate. Finished vials are sealed under sterile-filtered nitrogen; headspace oxygen is controlled to less than 2.0% because oxygen accelerates β-lactam degradation. Filling is performed on an isolator or open RABS line with continuous particulate monitoring at ≥0.5 µm and ≥5 µm, with the fill room maintained at ISO 14644-1 class 5. Depyrogenation tunnels for glass vials are set above 250°C, and the auger or vacuum drum filler is characterized for a fill-weight tolerance of ±1.5% against a 500 mg target. Release of the sterile API is controlled for sterility by USP <71> and for bacterial endotoxins by USP <85>. The API is manufactured under ICH Q7 GMP requirements. A production-scale failure mode observed with this type of crystalline carbapenem powder is electrostatic adhesion of fines to stainless steel contact parts; this is managed by maintaining relative humidity at 25–40% RH, rather than below 20% RH, where static discharge becomes acute and can interfere with fill-weight control.

Why Is the Final Dilution Restricted to 0.9% Sodium Chloride and 5% Dextrose Injection?

Reconstitution of a 500 mg vial with 10 mL of Sterile Water for Injection or 0.9% Sodium Chloride Injection produces a suspension with a pH of 4.5–5.5. The suspension is not intended for direct injection and is transferred into 100 mL of a compatible infusion diluent, yielding a final doripenem concentration of approximately 4.5 mg/mL. The pH window is critical because the carbapenem β-lactam ring undergoes hydroxide-catalyzed hydrolysis above pH 7. Lactated Ringer’s Injection and bicarbonate-containing admixtures are therefore excluded from the compatibility matrix. Dextrose 5% injection is acceptable because its slightly acidic matrix tends to buffer the admixture toward the lower end of the stability window. After final dilution, the solution is clear or slightly yellowish and is infused over 1 h. The reconstituted suspension before dilution should be used within 1 h at 25°C; the diluted admixture may be held at 25°C for not more than 4 h or at 2–8°C for up to 24 h. Infusion containers should be non-PVC or polyolefin; PVC may shorten the hold time by introducing plasticizer and oxygen transmission into a hydrolytically unstable β-lactam system. Hospital pharmacy automated compounding systems should be qualified against these temperature and pH boundaries rather than treating doripenem as a generic room-temperature-stable cephalosporin admixture.

Table 1. Diluent matrix after reconstitution of a 500 mg doripenem vial.

Subvisible particulate burden in the reconstituted suspension is not solely a release attribute; it is also a function of the diluent, the transfer technique, and the vial closure. The diluted infusion solution must meet the subvisible particulate requirements of USP <788> for large-volume injections above 100 mL, with light obscuration methods recording counts at ≥10 µm and ≥25 µm thresholds. Visible particulates are controlled according to USP <790>. Because doripenem is filled as a dry powder that forms a suspension before dilution, the release value for the dry vial is not directly equivalent to the final patient-ready unit; the final intravascular solution must be assessed after transfer into the infusion container. For endotoxin control, the parenteral limit under USP <85> is derived from the K/M equation where K is 5 EU/kg and M is the maximum dose in mg/kg. For a 2 g daily dose in a 70 kg adult, M is 28.6 mg/kg and the calculated limit is 0.17 EU/mg. In-line filters with positively charged nylon membranes are not recommended for carbapenem solutions because adsorption at the anionic carboxyl group can reduce drug recovery. Silicone oil droplets from disposable syringes can produce false particulate counts under light obscuration; this is addressed by using silicone-free transfer devices in the compounding suite. The dry vial must be handled as a suspension, and the first 1:10 dilution step should be completed without an in-line filter upstream of full dissolution to avoid filter plugging from undissolved crystalline fines.

Bicarbonate-Buffered Renal Replacement Fluids and β-Lactam Ring-Opening Kinetics

Doripenem is cleared by high-flux hemodialysis and continuous renal replacement therapy, so the injectable API enters clinical protocols where the diluted infusion may be co-administered near bicarbonate-based dialysate or replacement fluid. The β-lactam ring remains most stable at pH 4.5–5.5 and undergoes base-catalyzed hydrolysis in bicarbonate-containing fluids with pH values of 7.4–8.0. Published data for doripenem-specific degradation in bicarbonate-buffered renal replacement fluid is limited; however, the general carbapenem hydrolysis rate increases sharply when pH exceeds 7.0 and the fluid temperature is maintained at 35–37°C in the extracorporeal circuit. To prevent ring-opened impurities, doripenem should not be mixed in the same container with bicarbonate replacement fluid. In continuous veno-venous hemodiafiltration, doripenem is administered as a separate central line infusion; extracorporeal clearance depends on filter membrane type, ultrafiltration rate, and dialysate flow. Polysulfone and polyacrylonitrile high-flux membranes remove doripenem to a clinically relevant extent, requiring dosing adjustment according to renal function. A pharmacy preparation unit that primes a CRRT circuit with bicarbonate-containing solutions should flush the line with 0.9% sodium chloride before doripenem infusion to avoid local pH spikes at the Y-site. The sterile API retains its label-stability profile only if it is first diluted into 0.9% sodium chloride or 5% dextrose and then introduced through a dedicated lumen.

Conventional immediate-release tablet and capsule development is blocked at the first physiological barrier because doripenem is a polar, zwitterionic carbapenem with negligible oral absorption and gastric acid lability. A direct-compression tablet containing unprotected doripenem would release the API into simulated gastric fluid at USP <711> pH 1.2, where the β-lactam carbonyl is protonated and the ring becomes cleavage-prone. Published data for doripenem-specific oral pharmacokinetics is limited, and no approved oral product exists. Any oral feasibility program must start from a gastro-resistant matrix or enteric-coated multiparticulate system. Excipients that create an alkaline microenvironment, such as sodium bicarbonate, meglumine, or calcium carbonate, are contraindicated because high-pH microenvironments accelerate the same hydroxide-catalyzed degradation observed in infusion fluids above pH 7. Dry processing is mandatory; wet granulation with water or hydroalcoholic binders introduces hydrolysis and produces a sticky mass with poor granule hardness. Tablet compression of dry blends containing microcrystalline cellulose, crospovidone, and magnesium stearate can be carried out at relative humidity below 30% RH. Capsule filling with dry blends is feasible for small-scale animal studies, but the powder should not be filled into gelatin capsules that retain residual moisture. Hard gelatin shells conditioned to 10–15% moisture can transfer water to the API during storage and initiate potency loss.

Roller-Compacted Granules with Methacrylic Acid–Ethyl Acrylate Copolymer Coatings Allow Gastric Protection in Investigational Batches

Granule formation for a moisture-sensitive carbapenem is limited to dry granulation because aqueous binder addition is hydrolytically incompatible with the β-lactam ring. Roller compaction with a roll force of 15–25 kN/cm and a roll gap of 2–3 mm produces dense ribbons that are milled to a target granule fraction of 500–850 µm. The granules are then coated in a bottom-spray fluid-bed coater with a methacrylic acid–ethyl acrylate copolymer (1:1) dispersion, typically applied at a product temperature of 24–28°C and a spray rate of 3–5 g/min/kg. The coating level required for gastric resistance is 15–25% weight gain. Enteric polymer dissolution begins above pH 5.5, so the coated granules remain intact in the stomach and release doripenem in the upper small intestine. The process must be run with low-dew-point inlet air because the aqueous polymer dispersion can wet the substrate and initiate surface hydrolysis at the API-polymer interface. Cracking of the coating is a critical defect; a cracked enteric coat exposes the API to gastric fluid and can result in immediate potency loss. Published data for doripenem-specific enteric-coated granule formulations is limited; the ranges stated above are typical for methacrylic acid multiparticulates and must be verified for this carbapenem substrate.

Table 2. Investigational oral multiparticulate processing screening window.

When enteric-coated granules are filled into hard gelatin capsules, the primary stability risks shift from processing loss to residual water, coating migration, and mechanical damage during capsule filling. Capsule filling machines with dosator nozzles can crush dry-coated granules; tamping pins or vacuum dosators must be adjusted to minimize shear. Hard gelatin capsules conditioned to 10–15% moisture may transfer water to the dried granules during prolonged storage, raising the moisture content above the threshold where β-lactam hydrolysis accelerates. Capsule fill compositions should therefore use low-moisture hydroxypropyl methylcellulose capsules or include a desiccant in the primary package. In-process controls include disintegration testing in pH 1.2 buffer using the basket apparatus, where coated granules should resist disintegration for 2 h, followed by quantitative release in pH 6.8 phosphate buffer. The acceptance criterion for gastric resistance is not more than 10% release in the acid stage after 2 h. If the coating is damaged, release exceeds this limit immediately. The final dosage form remains investigational because oral bioavailability of doripenem is insufficient to support a therapeutic equivalence claim; the enteric-coated granule can serve only as a prototype for permeability-enhancement studies, not as a marketed oral product. Finished capsules are stored in amber glass bottles with silica gel desiccant and sealed with an induction liner to limit moisture ingress during stability evaluation.